Bright Green CEO says EB-5 program ‘gaining traction’

Bright Green Corporation CEO Gurvinder Singh said, in part, “We’ve experienced massive shifts within the industry since the start of 2024 – shifts that have presented exciting growth opportunities for Bright Green. I’ll begin with an update on the state of our groundbreaking EB-5 investment program in partnership with Asia Capital Pioneers Group. I’m thrilled to share with you that we have confirmed our first three applications through this partnership and have been informed that more than a dozen additional investors have taken steps to begin the program investment. To capitalize on this momentum, the team at ACPG just completed the first successful event on the 26th of May. This kicks off a series of events hosted by ACPG and featuring the Company, and the Company’s EB-5 program. With more than 100 potential investors in attendance at the first event, we are optimistic about the immense interest we’re experiencing, particularly as we look forward to future events in Dubai, Singapore and Malaysia. We will be sharing developments from these events on our Regional Center Website. With our EB-5 program gaining traction, we are moving full steam ahead with our prominent initiative to accelerate our commercialization of Schedule I and Schedule II controlled substances in the U.S., once all necessary approvals are obtained. We have submitted our DEA 2025 quota request for Schedule I and Schedule II substances, meaning that as of today, Bright Green has applied to produce 22 Schedule I and Schedule II controlled substances in total. If these quotas and our registration application are approved, we aim to handle 70% of all Marijuana, Marijuana extract, and Tetrahydrocannabinols production within the DEA’s program. We also aim to handle 70% of Mescaline production and 50% of Psilocybin and Psilocyn production taking place within the DEA’s program.”